137 results on '"Jebbink M"'
Search Results
2. Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
3. Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
4. Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
5. 1262P Combined molecular analysis of circulating tumour DNA and tumour tissue to identify osimertinib resistance.
6. Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting
7. 27P Influence of single nucleotide polymorphisms (SNPs) in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer
8. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
9. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
10. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
11. The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure
12. T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial
13. MA02.07 T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm+ NSCLC: Interim Analysis of a Phase II Trial
14. MA07.03 Paired Liquid and Tissues Biopsies to Guide Treatment for Patients That Progress on 2nd Line Osimertinib Treatment
15. 1261P Trastuzumab/pertuzumab combination therapy in advanced pre-treated HER2-mutated non-small cell lung cancer: Results of a DRUP trial cohort
16. 1740P Track and treat in NSCLC (TATIN) - ctDNA guided treatment of early resistance to second-line osimertinib treatment in patients with EGFR mutation positive (EGFRm) NSCLC
17. Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response
18. 1347P Peripheral osimertinib (osi) plasma trough concentration (Cmin,SS) as surrogate parameter for development and progression of brain metastasis (BM) in patients (pts) with EGFR+ advanced non-small cell lung cancer (aNSCLC)
19. Strategisch management voor medici
20. The force of HER2 – A druggable target in NSCLC?
21. Effects of somatostatin and loxiglumide on gallbladder motility
22. Medicus en vooruitkijken
23. Positionering strategisch management voor de medische praktijkvoering
24. Medicus en zijn behandelteam
25. Inleiding
26. Medicus en ondersteunend personeel
27. Medicus en strategische allianties
28. Medicus en zijn markt
29. Medicus en ruimte
30. Effect of loxiglumide (CR-1505) on bombesin- and meal-stimulated plasma cholecystokinin in man
31. The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure
32. Detection of New Viruses by VIDISCA : Virus Discovery Based on cDNA-Amplified Fragment Length Polymorphism
33. Human coronavirus NL63 infection is associated with group
34. Identification of novel human endogenous retroviral sequences belonging to the HERV-K family
35. Medicus en vooruitkijken.
36. Medicus en strategische allianties.
37. Medicus en ruimte.
38. Medicus en zijn behandelteam.
39. Medicus en ondersteunend personeel.
40. BackMatter.
41. Medicus en zijn markt.
42. Positionering strategisch management voor de medische praktijkvoering.
43. FrontMatter.
44. Trastuzumab-emtansine and osimertinib (TRAEMOS) combination therapy to target HER2 bypass track resistance in EGFR mutation positive NSCLC
45. Evolutionary relationships within a subgroup of HERV-K-related human endogenous retroviruses.
46. Identification of a unique group of human papillomavirus type 16 sequence variants among clinical isolates from Barbados
47. Effect of duodenal juice on bombesin-stimulated cholecystokinin release during loxigIumide administration in man
48. Effect of acute hyperglycaemia on gall bladder contraction induced by cholecystokinin in humans.
49. Detection and typing of human papillomaviruses present in fixed and stained archival cervical smears by a consensus polymerase chain reaction and direct sequence analysis allow the identification of a broad spectrum of human papillomavirus types
50. Strategisch management voor medici
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.